ABVC Signs A Term Sheet To Earn Licensing Fees Of Up To $20M And Royalties Of 5-12% Of Net Sales
Portfolio Pulse from Happy Mohamed
ABVC Biopharma, Inc. (NASDAQ:ABVC) has signed a term sheet with Xinnovation Therapeutics Co., Ltd for the exclusive licensing of ABV-1504 for Major Depressive Disorder (MDD) and ABV-1505 for Attention-Deficit/Hyperactivity Disorder in mainland China. The deal could bring in up to $20 million in licensing fees and 5-12% royalties on net sales, potentially generating around $50 million annually and $1 billion over the patent life of the products.
August 01, 2023 | 1:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The licensing deal with Xinnovation Therapeutics could bring significant revenues to ABVC Biopharma, potentially boosting its stock price in the short term.
The licensing deal with Xinnovation Therapeutics could bring in up to $20 million in licensing fees and 5-12% royalties on net sales for ABVC Biopharma. This significant potential revenue could positively impact the company's financial performance and, consequently, its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100